PATIENTS' PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

被引：1
|
作者：
Zeidan, A. [1 ]
Perepezko, K. [2 ]
Salimi, T. [3 ]
Washington, T. [3 ]
Epstein, R. [4 ]
机构：
[1] Yale Canc Ctr, Hematol, New Haven, CT USA
[2] CorEvitas Llc, Waltham, MA USA
[3] Taiho Oncol Inc, Princeton, NJ USA
[4] Epstein Hlth Llc, Woodcliff Lake, NJ USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O14
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes.
    Reljic, Tea
    Bhansali, Neera
    Komrokji, Rami S.
    Lin, Karen
    List, Alan F.
    Djulbegovic, Benjamin
    Fenstermacher, David A.
    Lancet, Jeffrey E.
    Miladinovic, Branko
    Kumar, Ambuj
    BLOOD, 2010, 116 (21) : 1628 - 1628
  • [42] Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes
    Dvirnyk, V. N.
    Kokhno, A. V.
    Glasko, E. N.
    Gemdjian, E. G.
    Dyagileva, O. A.
    Platonova, T. L.
    Parovichnikova, E. N.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (07) : 65 - 71
  • [43] A pilot study of decitabine in combination with arsenic trioxide for patients with myelodysplastic syndromes
    de Castro, C.
    Adams, D.
    Rizzieri, D.
    Moore, J.
    Gockerman, J.
    Diehl, L.
    Horwitz, M.
    Edmonds, E.
    Warzecho, J.
    LEUKEMIA RESEARCH, 2009, 33 : S134 - S134
  • [44] Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment
    Zeidan, Amer M.
    Jayade, Sayeli
    Schmier, Jordana
    Botteman, Marc
    Hassan, Audrey
    Ruiters, Desiree
    Hill, Kala
    Joshi, Namita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E185 - E198
  • [45] Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes
    Doll, DC
    Kasper, LM
    Taetle, R
    List, AF
    LEUKEMIA RESEARCH, 1998, 22 (01) : 7 - 12
  • [46] Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine
    Santini, Valeria
    Amato, Cristina
    De Pourcq, Sven
    della Seta, Roberta
    Caciagli, Barbara
    Raddi, Marco Gabriele
    Consagra, Angela
    Rigodanza, Luca
    Mattiuz, Giorgio
    Defina, Marzia
    Galimberti, Sara
    Maestrini, Giacomo
    Sanna, Alessandro
    BLOOD, 2023, 142
  • [47] Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria
    Bataller, Alex
    Montalban-Bravo, Guillermo
    Bazinet, Alexandre
    Valero, Yesid Alvarado
    Chien, Kelly S.
    Venugopal, Sangeetha
    Ishizawa, Jo
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Sasaki, Koji
    Issa, Ghayas C.
    Short, Nicholas J.
    Masarova, Lucia
    Daver, Naval
    Kadia, Tapan M.
    Colla, Simona
    Qiao, Wei
    Huang, Xuelin
    Kanagal-Shamanna, Rashmi
    Hendrickson, Stephany
    Ravandi, Farhad
    Jabbour, Elias
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [48] A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Griffiths, Elizabeth A.
    Roboz, Gail J.
    Busque, Lambert
    Wells, Richard A.
    Odenike, Olatoyosi
    Steensma, David P.
    Yee, Karen W. L.
    Faderl, Stefan
    Amrein, Philip C.
    Michaelis, Laura C.
    Kantarjian, Hagop M.
    Oganesian, Aram
    Lowder, James N.
    Azab, Mohammad
    Savona, Michael R.
    BLOOD, 2017, 130
  • [49] REFINED SEMI-PHYSIOLOGICAL POPULATION PHARMACOKINETIC (POPPK) MODEL FOR ORAL FIXED-DOSE COMBINATION DATA OF CEDAZURIDINE WITH DECITABINE IN MYELODYSPLASTIC SYNDROME PATIENTS.
    Oganesian, A.
    Burroughs, E.
    Chan, D.
    Azab, M.
    Elmokadem, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S51 - S51
  • [50] Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes
    Zhang, Zheng
    He, Qi
    Tao, Ying
    Guo, Juan
    Xu, Feng
    Wu, Ling-Yun
    Zhao, You-Shan
    Wu, Dong
    Zhou, Li-Yu
    Su, Ji-Ying
    Song, Lu-Xi
    Xiao, Chao
    Li, Xiao
    Chang, Chun-Kang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (02): : 454 - 465
12345